Ajay Kirtane, MD: What We Can Learn From the ECLIPSE Trial and the OPTIMUM Registry
By DocWire News Editors - Last Updated: May 2, 2023DocWire News continues its conversation with Ajay Kirtane, MD, Associate Professor of Medicine at Columbia University Medical Center, who discusses the exciting data coming from two new interventional studies: The ECLIPSE (Evaluation of Treatment Strategies for Severe CalcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug Eluting Stents) Trial, and the observational OPTIMUM (Outcomes of Surgically Ineligible Patients With Multivessel CAD) Registry analysis.
Advertisement
Advertisement
Related Posts
The REPAIR study offers the most comprehensive real-world assessment of outcomes after mitral TEER.
The ROLLER COASTR-EPIC22 trial is the first randomized head-to-head comparison of three plaque modification techniques.
Patients between the ages of 50 and 70 years with a mechanical heart valve have better long-term survival.
Coronary Sinus Reducer Demonstrates Long-Term Efficacy in Refractory Angina: Insights from REDUCER-I
The observational REDUCER-I study aims to evaluate the real-world safety and effectiveness of the coronary sinus reducer.
Dr. Amit Goyal details a study which explored the role of coronary sinus reducer in Coronary microvascular dysfunction.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.